Eli Lilly (LLY)
829.42
+0.00 (0.00%)
NYSE · Last Trade: Apr 24th, 5:23 AM EDT
Detailed Quote
Previous Close | 829.42 |
---|---|
Open | - |
Bid | 819.20 |
Ask | 824.58 |
Day's Range | N/A - N/A |
52 Week Range | 677.09 - 972.53 |
Volume | 415 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 6.000 (0.72%) |
1 Month Average Volume | 3,816,312 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
Edwards Lifesciences stock was flat late Wednesday after the medtech company beat profit views and delivered in-line sales.
Via Investor's Business Daily · April 23, 2025
Via The Motley Fool · April 23, 2025
Bristol Myers' Cobenfy missed its primary endpoint in the Phase 3 ARISE trial but showed symptom improvement in certain subgroups.
Via Benzinga · April 23, 2025
The company unveiled three seventh-generation robotaxi models developed through its partnerships with Toyota, BAIC, and GAC at the Shanghai International Automobile Industry Exhibition on Wednesday.
Via Stocktwits · April 23, 2025
According to a CNBC report, the company filed lawsuits against Mochi Health, Fella Health, Willow Health, and Henry Med on Wednesday, alleging that they deceived consumers about “untested, unapproved drugs.”
Via Stocktwits · April 23, 2025
Boston Scientific stock jumped Wednesday after the medtech company beat first-quarter expectations and hiked its sales view.
Via Investor's Business Daily · April 23, 2025
Via Benzinga · April 23, 2025
Via The Motley Fool · April 23, 2025
The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations.
Via Benzinga · April 23, 2025
Via The Motley Fool · April 23, 2025
The competitive landscape for GLP-1 agonist weight loss drugs has undergone a significant shake-up.
Via The Motley Fool · April 23, 2025
Today's Research Daily features a real-time scorecard of the Q1 earnings season and freshly updated research reports on 16 major stocks, including NVIDIA Corporation, Alphabet Inc., and Berkshire Hathaway Inc..
Via Talk Markets · April 22, 2025
Via The Motley Fool · April 22, 2025
Intuitive Surgical stock plunged late Tuesday on worries about potential tariffs. The impact "could be material."
Via Investor's Business Daily · April 22, 2025
Roche to invest $50 billion in U.S. over five years, adding 12,000+ jobs and expanding manufacturing, R&D, and export capacity across eight states.
Via Benzinga · April 22, 2025
Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for May 1.
Via Benzinga · April 22, 2025
Reports suggest Novo Nordisk has asked the FDA to approve its oral semaglutide, two years after reporting a Phase 3 win.
Via Investor's Business Daily · April 22, 2025
Via The Motley Fool · April 22, 2025
Via The Motley Fool · April 22, 2025
The request reportedly came two years after a Phase 3 study of Rybelsus, an oral formulation of semaglutide, which showed successful results.
Via Stocktwits · April 22, 2025
Pfizer Inc (NYSE:PFE) is scheduled to release its first quarter 2025 earnings on 29 April.
Via Benzinga · April 21, 2025
Last week, thematic and leveraged ETFs performed well, such as DJTU, LLYX, NFXL, DECO, and MSTY, despite market concerns. Tech sector was hit by geopolitical tension and hawkish central bank comments. Earnings were mixed, with UNH cutting its full-year forecast.
Via Benzinga · April 21, 2025
Via The Motley Fool · April 21, 2025